Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial
Lobeglitazone as an add-on to empagliflozin and metformin significantly improved glycaemic control in patients with T2DM inadequately controlled on metformin and empagliflozin dual therapy. The treatment was well tolerated, with a low incidence of adverse events.
Authors
- Cheol‐Young Park (ORCID: https://orcid.org/0000-0002-9415-9965)
- Kun‐Ho Yoon (ORCID: https://orcid.org/0000-0002-9109-2208)
- So Hun Kim (ORCID: https://orcid.org/0000-0002-2554-3664)
- In‐Kyung Jeong (ORCID: https://orcid.org/0000-0001-7857-546X)
- Sang Yong Kim (ORCID: https://orcid.org/0000-0002-3902-622X)
- Kyung Wan Min
- Da Hea Seo (ORCID: https://orcid.org/0000-0003-2767-0293)
- Ho Sang Sohn
Institutions
- Inha University (KR)
- Yonsei University (KR)
- Eulji University (KR)
- Daegu Catholic University (KR)
- St. Mary's Hospital (US)
- Chosun University Hospital (KR)
- Kangbuk Samsung Hospital (KR)
- Kyung Hee University Hospital at Gangdong (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Eulji Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1111/dom.70257
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00